{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T11:30:08Z","timestamp":1794655808589,"version":"4.9.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T00:00:00Z","timestamp":1576195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T00:00:00Z","timestamp":1576195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Vivet Therapeutics."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Progressive familial intrahepatic cholestasis type 3 (PFIC3) is a rare monogenic disease caused by mutations in the\n                    <jats:italic>ABCB4<\/jats:italic>\n                    gene, resulting in a reduction in biliary phosphatidylcholine. Reduced biliary phosphatidylcholine cannot counteract the detergent effects of bile salts, leading to cholestasis, cholangitis, cirrhosis and ultimately liver failure. Here, we report results from treating two- or five-week-old\n                    <jats:italic>Abcb4<\/jats:italic>\n                    <jats:sup>\u2212\/\u2212<\/jats:sup>\n                    mice with an AAV vector expressing human\n                    <jats:italic>ABCB4<\/jats:italic>\n                    , resulting in significant decreases of PFIC3 disease biomarkers. All male mice achieved a sustained therapeutic effect up through 12 weeks, but the effect was achieved in only 50% of females. However, two-week-old females receiving a second inoculation three weeks later maintained the therapeutic effect. Upon sacrifice, markers of PFIC3 disease such as, hepatosplenomegaly, biliary phosphatidylcholine and liver histology were significantly improved. Thus, AAV-mediated gene therapy successfully prevented PFIC3 symptoms in a clinically relevant mouse model, representing a step forward in improving potential therapy options for PFIC3 patients.\n                  <\/jats:p>","DOI":"10.1038\/s41467-019-13614-3","type":"journal-article","created":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T06:04:00Z","timestamp":1576217040000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Gene therapy for progressive familial intrahepatic cholestasis type 3 in a clinically relevant mouse model"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3584-644X","authenticated-orcid":false,"given":"Nicholas D.","family":"Weber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Odriozola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2289-1719","authenticated-orcid":false,"given":"Javier","family":"Mart\u00ednez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7687-6151","authenticated-orcid":false,"given":"Veronica","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3744-8445","authenticated-orcid":false,"given":"Anne","family":"Douar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9331-0926","authenticated-orcid":false,"given":"Bernard","family":"B\u00e9nichou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Gonz\u00e1lez-Aseguinolaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6861-6579","authenticated-orcid":false,"given":"Cristian","family":"Smerdou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,13]]},"reference":[{"key":"13614_CR1","doi-asserted-by":"crossref","unstructured":"Davit-Spraul, A., Gonzales, E., Baussan, C. & Jacquemin, E. Progressive familial intrahepatic cholestasis. Orphanet J. Rare Dis. 4, 1 (2009).","DOI":"10.1186\/1750-1172-4-1"},{"key":"13614_CR2","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S1388-1981(00)00053-6","volume":"1486","author":"P Borst","year":"2000","unstructured":"Borst, P., Zelcer, N. & van Helvoort, A. ABC transporters in lipid transport. Biochim. Biophys. Acta 1486, 128\u2013144 (2000).","journal-title":"Biochim. Biophys. Acta"},{"key":"13614_CR3","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1053\/gast.2001.23984","volume":"120","author":"E Jacquemin","year":"2001","unstructured":"Jacquemin, E. et al. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology 120, 1448\u20131458 (2001).","journal-title":"Gastroenterology"},{"key":"13614_CR4","doi-asserted-by":"crossref","unstructured":"Gonzales, E., Spraul, A. & Jacquemin, E. Clinical utility gene card for: progressive familial intrahepatic cholestasis type 3. Eur. J. Hum. Genet. 22, 572\u00a0(2014).","DOI":"10.1038\/ejhg.2013.188"},{"key":"13614_CR5","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/hep.510250303","volume":"25","author":"E Jacquemin","year":"1997","unstructured":"Jacquemin, E. et al. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis. Hepatology 25, 519\u2013523 (1997).","journal-title":"Hepatology"},{"key":"13614_CR6","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/j.cell.2017.11.049","volume":"171","author":"D Lillicrap","year":"2017","unstructured":"Lillicrap, D. FIX it in one go: enhanced factor IX gene therapy for hemophilia B. Cell 171, 1478\u20131480 (2017).","journal-title":"Cell"},{"key":"13614_CR7","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","volume":"371","author":"AC Nathwani","year":"2014","unstructured":"Nathwani, A. C. et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N. Engl. J. Med. 371, 1994\u20132004 (2014).","journal-title":"N. Engl. J. Med."},{"key":"13614_CR8","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","volume":"390","author":"SJ Russell","year":"2017","unstructured":"Russell, S. J. et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet 390, 849\u2013860 (2017).","journal-title":"Lancet"},{"key":"13614_CR9","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/0092-8674(93)90380-9","volume":"75","author":"JJM Smit","year":"1993","unstructured":"Smit, J. J. M. et al. Homozygous disruption of the murine Mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver-disease. Cell 75, 451\u2013462 (1993).","journal-title":"Cell"},{"key":"13614_CR10","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.ajpath.2014.10.013","volume":"185","author":"N Ikenaga","year":"2015","unstructured":"Ikenaga, N. et al. A new Mdr2(\u2212\/\u2212) mouse model of sclerosing cholangitis with rapid fibrosis progression, early-onset portal hypertension, and liver cancer. Am. J. Pathol. 185, 325\u2013334 (2015).","journal-title":"Am. J. Pathol."},{"key":"13614_CR11","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.jhep.2005.06.025","volume":"43","author":"Y Popov","year":"2005","unstructured":"Popov, Y., Patsenker, E., Fickert, P., Trauner, M. & Schuppan, D. Mdr2 (Abcb4)\u2212\/\u2212 mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J. Hepatol. 43, 1045\u20131054 (2005).","journal-title":"J. Hepatol."},{"key":"13614_CR12","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1002\/j.1460-2075.1987.tb02653.x","volume":"6","author":"AM Van der bliek","year":"1987","unstructured":"Van der bliek, A. M. et al. The human Mdr3-gene encodes a novel P-glycoprotein homolog and gives rise to alternatively spliced messenger-Rnas in liver. EMBO J. 6, 3325\u20133331 (1987).","journal-title":"EMBO J."},{"key":"13614_CR13","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/hep.26335","volume":"58","author":"T Potikha","year":"2013","unstructured":"Potikha, T. et al. Interstrain differences in chronic hepatitis and tumor development in a murine model of inflammation-mediated hepatocarcinogenesis. Hepatology 58, 192\u2013204 (2013).","journal-title":"Hepatology"},{"key":"13614_CR14","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1158\/1541-7786.MCR-07-0172","volume":"5","author":"M Katzenellenbogen","year":"2007","unstructured":"Katzenellenbogen, M. et al. Molecular mechanisms of liver carcinogenesis in the mdr2-knockout mice. Mol. Cancer Res. 5, 1159\u20131170 (2007).","journal-title":"Mol. Cancer Res."},{"key":"13614_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12880-015-0058-z","volume":"15","author":"PR Territo","year":"2015","unstructured":"Territo, P. R. et al. Evaluation of 11C-acetate and 18F-FDG PET\/CT in mouse multidrug resistance gene-2 deficient mouse model of hepatocellular carcinoma. BMC Med. Imaging 15, 1\u201312 (2015).","journal-title":"BMC Med. Imaging"},{"key":"13614_CR16","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.jhep.2017.01.027","volume":"66","author":"M Zhou","year":"2017","unstructured":"Zhou, M. et al. Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19\/FGF15. J. Hepatol. 66, 1182\u20131192 (2017).","journal-title":"J. Hepatol."},{"key":"13614_CR17","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1073\/pnas.0908867107","volume":"107","author":"H Barash","year":"2010","unstructured":"Barash, H. et al. Accelerated carcinogenesis following liver regeneration is associated with chronic inflammation-induced double-strand DNA breaks. Proc. Natl Acad. Sci. USA 107, 2207\u20132212 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"13614_CR18","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/S2210-7401(12)70018-9","volume":"36","author":"E Jacquemin","year":"2012","unstructured":"Jacquemin, E. Progressive familial intrahepatic cholestasis. Clin. Res. Hepatol. Gastroenterol. 36, S26\u2013S35 (2012).","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"13614_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30773.","author":"SM Siew","year":"2019","unstructured":"Siew, S. M. et al. Prevention of Cholestatic Liver Disease and Reduced Tumorigenicity in a Murine Model of PFIC Type 3 Using Hybrid AAV-piggyBac Gene Therapy. Hepatology. https:\/\/doi.org\/10.1002\/hep.30773. (2019).","journal-title":"Hepatology"},{"key":"13614_CR20","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/978-1-4939-8730-6_18","volume":"1850","author":"VP Mauro","year":"2018","unstructured":"Mauro, V. P. & Chappell, S. A. Considerations in the use of codon optimization for recombinant protein expression. Methods Mol. Biol. 1850, 275\u2013288 (2018).","journal-title":"Methods Mol. Biol."},{"key":"13614_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jhep.2019.03.021","volume":"71","author":"SJ Aronson","year":"2019","unstructured":"Aronson, S. J. et al. Liver-directed gene therapy results in long-term correction of progressive familial intrahepatic cholestasis type 3 in mice. Hepatology 71, 153\u2013162 (2019).","journal-title":"Hepatology"},{"key":"13614_CR22","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1053\/j.gastro.2011.04.002","volume":"141","author":"E Breous","year":"2011","unstructured":"Breous, E., Somanathan, S., Bell, P. & Wilson, J. M. Inflammation promotes the loss of adeno-associated virus-mediated transgene expression in mouse liver. Gastroenterology 141, 348\u2013357 (2011).","journal-title":"Gastroenterology"},{"key":"13614_CR23","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/jgm.1496","volume":"12","author":"C Hu","year":"2010","unstructured":"Hu, C., Busuttil, R. W. & Lipshutz, G. S. RH10 provides superior transgene expression in mice when compared with natural AAV serotypes for neonatal gene therapy. J. Gene Med. 12, 766\u2013778 (2010).","journal-title":"J. Gene Med."},{"key":"13614_CR24","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1089\/hum.2009.031","volume":"20","author":"A Pa\u00f1eda","year":"2009","unstructured":"Pa\u00f1eda, A. et al. Effect of adeno-associated virus serotype and genomic structure on liver transduction and biodistribution in mice of both genders. Hum. Gene Ther. 20, 908\u2013917 (2009).","journal-title":"Hum. Gene Ther."},{"key":"13614_CR25","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1089\/hum.2006.17.601","volume":"17","author":"P Berraondo","year":"2006","unstructured":"Berraondo, P. et al. Intrahepatic injection of recombinant adeno-associated virus serotype 2 overcomes gender-related differences in liver transduction. Hum. Gene Ther. 17, 601\u2013610 (2006).","journal-title":"Hum. Gene Ther."},{"key":"13614_CR26","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1182\/blood-2002-09-2889","volume":"102","author":"AM Davidoff","year":"2003","unstructured":"Davidoff, A. M., Ng, C. Y., Zhou, J., Spence, Y. & Nathwani, A. C. Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway. Blood 102, 480\u2013488 (2003).","journal-title":"Blood"},{"key":"13614_CR27","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1053\/gast.2000.20222","volume":"119","author":"JML De Vree","year":"2000","unstructured":"De Vree, J. M. L. et al. Correction of liver disease by hepatocyte transplantation in a mouse model of progressive familial intrahepatic cholestasis. Gastroenterology 119, 1720\u20131730 (2000).","journal-title":"Gastroenterology"},{"key":"13614_CR28","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s10545-017-0053-3","volume":"40","author":"J Baruteau","year":"2017","unstructured":"Baruteau, J., Waddington, S. N., Alexander, I. E. & Gissen, P. Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects. J. Inherit. Metab. Dis. 40, 497\u2013517 (2017).","journal-title":"J. Inherit. Metab. Dis."},{"key":"13614_CR29","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.omtm.2016.12.010","volume":"4","author":"SO Han","year":"2017","unstructured":"Han, S. O. et al. Low-dose liver-targeted gene therapy for pompe disease enhances therapeutic efficacy of ERT via immune tolerance induction. Mol. Ther. Methods Clin. Dev. 4, 126\u2013136 (2017).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"13614_CR30","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S1665-2681(19)30771-9","volume":"14","author":"B Frider","year":"2015","unstructured":"Frider, B. et al. Reversal of advanced fibrosis after long-term ursodeoxycholic acid therapy in a patient with residual expression of MDR3. Ann. Hepatol. 14, 745\u2013751 (2015).","journal-title":"Ann. Hepatol."},{"key":"13614_CR31","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1136\/gutjnl-2014-306896","volume":"64","author":"R Gordo-Gilart","year":"2015","unstructured":"Gordo-Gilart, R. et al. Functional analysis of ABCB4 mutations relates clinical outcomes of progressive familial intrahepatic cholestasis type 3 to the degree of MDR3 floppase activity. Gut 64, 147\u2013155 (2015).","journal-title":"Gut"},{"key":"13614_CR32","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1016\/j.ymthe.2017.05.003","volume":"25","author":"A Majowicz","year":"2017","unstructured":"Majowicz, A. et al. Successful repeated hepatic gene delivery in mice and non-human primates achieved by sequential administration of AAV5ch and AAV1. Mol. Ther. 25, 1831\u20131842 (2017).","journal-title":"Mol. Ther."},{"key":"13614_CR33","first-page":"1524","volume":"74","author":"C Rivi\u00e8re","year":"2006","unstructured":"Rivi\u00e8re, C., Danos, O. & Douar, A. M. Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice. Gene Ther. 74, 1524\u20131532 (2006).","journal-title":"Gene Ther."},{"key":"13614_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06621-3","volume":"9","author":"A Meliani","year":"2018","unstructured":"Meliani, A. et al. Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration. Nat. Commun. 9, 4098 (2018).","journal-title":"Nat. Commun."},{"key":"13614_CR35","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1525-0016(02)00060-6","volume":"7","author":"MG Kramer","year":"2003","unstructured":"Kramer, M. G. et al. In vitro and in vivo comparative study of chimeric liver-specific promoters. Mol. Ther. 7, 375\u2013385 (2003).","journal-title":"Mol. Ther."},{"key":"13614_CR36","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1101\/gad.3.7.1019","volume":"3","author":"N Levitt","year":"1989","unstructured":"Levitt, N., Briggs, D., Gil, A. & Proudfoot, N. J. Definition of an efficient synthetic poly(a) site. Gene Dev. 3, 1019\u20131025 (1989).","journal-title":"Gene Dev."},{"key":"13614_CR37","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.jhep.2015.09.014","volume":"64","author":"O Murillo","year":"2016","unstructured":"Murillo, O. et al. Long-term metabolic correction of Wilson\u2019s disease in a murine model by gene therapy. J. Hepatol. 64, 419\u2013426 (2016).","journal-title":"J. Hepatol."},{"key":"13614_CR38","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1089\/10430349950017734","volume":"10","author":"G Zhang","year":"1999","unstructured":"Zhang, G., Budker, V. & Wolff, J. A. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum. Gene Ther. 10, 1735\u20131737 (1999).","journal-title":"Hum. Gene Ther."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-13614-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-13614-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-13614-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T21:25:01Z","timestamp":1671225901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-13614-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,13]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["13614"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-13614-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,13]]},"assertion":[{"value":"21 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Drs. Weber, Ferrer, Douar, B\u00e9nichou, and Gonz\u00e1lez-Aseguinolaza are all employees of Vivet Therapeutics, a startup biopharmaceutical company developing gene therapy approaches for treatment of rare metabolic diseases. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5694"}}